Search results
Remdesivir is approved, or authorized for emergency use, to treat COVID‑19 in many countries. [19] Remdesivir has been authorized for emergency use in India, [54] Singapore, [55] and approved for use in Japan, [56] the European Union, the United States, and Australia for people with severe symptoms. [13] [15] [57] [58] [59] [60] [61] [62] [63]
29 kwi 2020 · To answer the first question, remdesivir is owned by Gilead Sciences, a US biotechnology company. Gilead got its first patent for the drug in 2017 when the company was originally targeting it...
28 paź 2020 · Two days after the results from China and the United States came out, FDA granted remdesivir an emergency use authorization (EUA)—a temporary status that is far from full approval—for use in severe COVID-19 patients. The agency cited the NIH trial data, but not the other study.
We review clinical development of remdesivir, a prodrug with a demonstrated ability to inhibit SARS-CoV-2 replication, which supports its clinical evaluation for COVID-19 treatment.
22 kwi 2022 · Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date.
27 maj 2020 · The report from Beigel et al. shows that remdesivir provides moderate clinical benefit in the treatment of patients with Covid-19. These findings are a step forward on the road to...
Subsequent evaluation by numerous virology laboratories demonstrated the ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2. Here, we provide an overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness.
